Home > List All Publishers > La Merie Publishing

La Merie Publishing

La Merie Business Intelligence is focused on Research and Development in the Biopharmaceutical Industry. La Merie provides information about biopharmaceutical R&D and competitive intelligence by Publishing, Consultancy and its Biotech Portal PipelineReview.com. The information is retrieved from La Merie’s in house R&D database, news portal and direct as well as desktop searches. La Merie has a focus on Biologics, including antibodies, proteins, peptides, vaccines, RNA, DNA and cell therapy.

La Merie publishes Competitor Analysis Reports, Brief Reports and Full Reports. The Competitor Analysis Series delivers NO-FRILLS , but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies.
The information is provided in a tabular format and fully referenced. Competitor analysis reports can be purchased as a la carte or obtained by subscribing to R&D Pipeline News. R&D Pipeline News is published weekly 50-times a year and each issue contains competitor evaluations. Individual products from the Competitor Analysis Series and R&D Pipeline News are elaborated by independent analysts of La Merie Business Intelligence. Brief Reports on Target Pipelines include assessment of the scientific as well as business perspective of new targets. Full reports provide in-depth analysis of product portfolios, R&D pipelines, competitive environment and a critical assessment of the pipeline perspective.

List of reports from La Merie Publishing

R&D Pipeline News - Technology Edition: 1-Month Subscription periodical \| published by: La Merie Publishing ... R&D Pipeline News Technology Edition will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given ... \| more...	$140.00
R&D Pipeline News - Therapeutic Area Edition: 1-Month Subscription periodical \| published by: La Merie Publishing ... R&D Pipeline News Therapeutic Area Edition will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a ... \| more...	$140.00
R&D Pipeline News - Therapeutic Area Edition: 1-Year Subscription periodical \| published by: La Merie Publishing ... R&D Pipeline News Therapeutic Area Edition will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a ... \| more...	$1,100.00
R&D Pipeline News - Technology Edition: 1-Year Subscription periodical \| published by: La Merie Publishing ... R&D Pipeline News Technology Edition will keep you up-to-date with the latest R&D projects of the biopharmaceutical industry, with all the relevant treatment modalities and with competitive information about ongoing R&D projects for a given ... \| more...	$1,100.00
Competitor Analysis: Adenosine Receptor Agonists & Antagonists 5/4/2008 \| published by: La Merie Publishing ... clinical development of Adenosine Receptor Agonists & Antagonistsas of May 2008. The report includes a compilation of current active projects in research and development of agonists and antagonists of the adenosine receptor subtypes 1, 2A, ... \| more... Search inside this report	$175.00
Competitor Analysis: G-CSF & GM-CSF 5/9/2008 \| published by: La Merie Publishing ... and next generation, longer acting products or new uses of G-CSF as of May 2008. The report includes a compilation of currently marketed branded and off-patent G-CSF and GM-CSF proudcts for treatment of chemotherapy-induced neutropenia. ... \| more... Search inside this report	$345.00
Competitor Analysis: Aurora Kinase Inhibitors 5/23/2008 \| published by: La Merie Publishing ... targeting aurora A, B and C kinase (aurora pan-kinase), aurora A and B kinase, aurora A kinase, aurora B kinase, not specified aurora kinase inhibitors and dual as well as multi-target aurora kinase with e.g. ... \| more... Search inside this report	$175.00
Competitor Analysis: Antihypertensives 6/13/2008 \| published by: La Merie Publishing ... information about the market size of the largest drug class for treatment of arterial hypertension, i.e. angiotensin receptor blockers. Among the companies active in the field of new antihypertensives are Sanofi-Aventis, Daiichi-Sankyo, Bristol-Myers Squibb, GlaxoSmithKline, ... \| more... Search inside this report	$410.00
Competitor Analysis: Integrin Antagonists 6/29/2008 \| published by: La Merie Publishing ... cancer, AMD, rheumatoid arthritis. Integrin targets include alpha4/beta1/7, alphaV/beta3/5, alpha5/beta1, VLA4 and others. Among the companies active in the field of new integrin antagonists are Biogen Idec and Elan, Roche, GlaxoSmithKline, J&J, Pfizer, Eisai and ... \| more... Search inside this report	$345.00
Competitor Analysis: Alzheimer’s Disease Antibodies 7/6/2008 \| published by: La Merie Publishing ... companies active in the field of new antibodies for passive immunotherapy of Alzheimer’s disease Wyeth, Elan, Pfizer, Roche and many others. The report includes a compilation of current active projects in research and development of ... \| more... Search inside this report	$140.00
Competitor Analysis: Antiviral Antibodies 7/13/2008 \| published by: La Merie Publishing ... respiratory syncytial virus (RSV), human immunedeficiency virus (HIV), influenza, rabies, smallpox and West Nile virus. Among the companies active in the field are mostly biotech companies. The report includes a compilation of current active projects ... \| more... Search inside this report	$275.00
Competitor Analysis: Immunotherapy of S. aureus Infections 7/20/2008 \| published by: La Merie Publishing ... of current active projects in research and development of novel antibodies and vaccines against S. aureus. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class ... \| more... Search inside this report	$70.00
Competitor Analysis: Antithrombotics 8/5/2008 \| published by: La Merie Publishing ... includes 2007 sales figures of the major products for low-molecular weight heparins (LMWH), specific indirect F. Xa inhibitor, direct thrombin inhibitors, antithrombin III, activated protein C (aPC) and inhibitors of platelet aggregation via the ADP ... \| more... Search inside this report	$685.00
Competitor Analysis: MTP Inhibitors 9/14/2008 \| published by: La Merie Publishing ... compilation of current active projects in research and development of novel MTP inhibitors. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, Company, ... \| more... Search inside this report	$70.00
Competitor Analysis: CETP Inhibitors 9/14/2008 \| published by: La Merie Publishing ... a compilation of current active projects in research and development of novel CETP inhibitors. Competitor projects are listed in a tabular format providing Information on: Drug Codes, Target / Mechanism of Action, Class of Compound, ... \| more... Search inside this report	$70.00
Competitor Analysis: HDL Raising Therapies 9/14/2008 \| published by: La Merie Publishing ... and approaches for raising high density lipoprotein cholesterol (HDL-C) are evaluated for competitive projects: Cholesteryl Ester Transfer Protein (CETP) Inhibitors; Niacin-Related Compounds (nicotinic acid receptor agonists); Apolipoprotein A-I (apo A-I), reconstituted HDL and HDL Mimetics ... \| more... Search inside this report	$345.00
Competitor Analysis: Human Growth Hormone (hGH) 10/5/2008 \| published by: La Merie Publishing ... hormone deficiency )GHD) in childrens and adults and related diseases. The report includes an evaluation of the hGH market size in 2007 based on published data and provides company pipelines in the field of hGH. ... \| more... Search inside this report	$410.00
Competitor Analysis: MEK Inhibitors 10/23/2008 \| published by: La Merie Publishing ... the companies active in the field of MEK inhibitors are Big Pharma and kinase inhibitor specialist biotech companies. The report includes a compilation of current active projects in research and development of MEK Inhibitors. Competitor ... \| more... Search inside this report	$105.00
Competitor Analysis: Cannabinoid CB1 receptor antagonists 11/3/2008 \| published by: La Merie Publishing ... diseases. First generation cannabinoid type 1 (CB1) receptor antagonists are directed against CB1 receptors in the brain and in peripheral tissues such as adipocytes. Acomplia (rimonabant) from Sanofi-Aventis is the only representative of this class ... \| more... Search inside this report	$175.00
Competitor Analysis: Sodium-dependent glucose (co-) transporter (SGLT) Inhibitors 11/4/2008 \| published by: La Merie Publishing ... (SGLT are specifically expressed in the intestines (SGLT-1) and kidneys (SGLT-1). Inhibitors of SGLT-1 suppress absorption of glucose from the gut, while SGLT-2 inhibitors block the reabsorptoin of glucose from the renal filtrate. Thus, SGLT ... \| more... Search inside this report	$140.00
Competitor Analysis: GLP-1 Receptor Agonists 11/4/2008 \| published by: La Merie Publishing ... Binding of glucagon-like peptide-1 (GLP-1) analogs or agonists to the GLP receptor induces insulin secretion from pancreatic beta cells. Exendin (Byetta) is the first representative of this new class of incretin mimetics, first approved in ... \| more... Search inside this report	$275.00
Competitor Analysis: Dipeptidyl peptidase IV (DPP-IV) Inhibitors 11/4/2008 \| published by: La Merie Publishing ... inhibitors are a new approach to the treatment of type 2 diabetes. The efficacy of DPP-IV inhibitors is mediated primarily via stabilization of the incretin hormones glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). ... \| more... Search inside this report	$205.00
Diabetes Drug Pipeline 11/7/2008 \| published by: La Merie Publishing ... overview of the major marketed diabetes drugs and the respective markets sizes and describes the corporate diabetes drug product portfolios and R&D pipelines of more than 160 companies worldwide. The report contains seven chapters in ... \| more... Search inside this report	$1,700.00
Competitor Analysis: Emerging Diabetes Drugs 11/7/2008 \| published by: La Merie Publishing ... the established targets PPAR agonists, DPP-IV inhibitors, GLP-1 receptor agonists and SGLT inhibitors. The report also includes the diabetes R&D portfolios of those companies with emerging diabetes drugs (incl. R&D projects for established targets). Emerging ... \| more... Search inside this report	$820.00
Competitor Analysis: Interferon 11/22/2008 \| published by: La Merie Publishing ... diseases, cancer and multiple sclerosis, respectively. Total sales of the major interferon alpha, beta and gamma products in 2007 were in excess of US$ 7.2 bln, the majority (US$ 4.6 bln) attributable to beta interferons ... \| more... Search inside this report	$550.00

< prev 1 2 3 4 5 6 next >